Advertisement

Topics

CymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9

20:00 EDT 1 Aug 2016 | Globe Newswire

NEWARK, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that it will host a conference call and live audio webcast on Tuesday, August 9th at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2016.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally.

To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company’s website at http://ir.cymabay.com/events.

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. MBX-8025 is a potent, selective, orally active PPARδ agonist. CymaBay has recently completed a Phase 2 study of MBX-8025 in patients with primary biliary cholangitis as well as a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications.  Previously, a Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile.  Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia.

For additional information about CymaBay visit www.cymabay.com.

Contact:	
Sujal Shah			
CymaBay Therapeutics, Inc.	
(510) 293-8800			
Investors@CymaBay.com	

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "CymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...